The prescribing information addresses this directly. It states that a missed dose may be given within five days of the scheduled day, and that if more than five days have passed the missed dose is skipped and the next one taken on the normal day. Everything beyond that window, including longer gaps and whether re-escalation is needed, belongs to the prescriber.
Where the label stops and the conversation starts
Two labeled statements cover routine slips. One is the five-day window described above. The other is that the weekly injection day can be moved when necessary, provided at least 48 hours separate two doses. Both apply to the approved product, and both are written for occasional variation rather than as a system for managing chronic irregularity.
What the label does not contain is a rule for a three-week gap, a rule for what happens after a pharmacy delay, or a method for compensating for lost time. Those situations exist and are common, but they are handled case by case rather than by formula, because the right answer depends on where the person was in their schedule, what else they take, and how they tolerated treatment before the interruption.
The instinct to make up a missed week by giving extra is the wrong one and is not supported anywhere in the labeling.
The five-day statement gets repeated widely because it is one of the few clear rules in the labeling. Henry Meds and Ro restate it, HealthRX carries the same guidance on its page for Ozempic, and manufacturer resources from NovoCare Pharmacy and LillyDirect echo it for the branded pen. Repeating the rule is fine. The trouble starts when a page reads as though it also covers a three-week gap, which none of them can, since that answer depends on the individual prescription.
Why the tolerance for a short delay exists
Semaglutide has a long half-life, around one week, which is what allows once-weekly administration in the first place. Concentrations do not collapse the day after a dose is due. They decline gradually, which is why a delay of a few days is a smaller event than the equivalent delay would be with a daily medication.
The same pharmacology explains why steady state takes weeks to establish rather than days. A single delayed dose nudges a curve that was built over more than a month. A run of missed weeks dismantles it.
What a longer gap actually changes
Three things shift after an extended interruption, and they are worth separating because patients tend to worry about the wrong one.
Glycemic control drifts back toward where it was, which is the clinically relevant part for anyone taking this for type 2 diabetes. Tolerance to gastrointestinal effects fades, so resuming at the previous amount after a long absence can feel like starting over. And the schedule itself needs rebuilding, since the anchor day is no longer meaningful.
Withdrawal studies of semaglutide in weight management showed weight and cardiometabolic measures moving back toward baseline after treatment stopped, which is consistent with what happens when any chronic therapy is interrupted rather than being unique to this drug. The practical implication is the same either way: a gap is a clinical event, not an administrative one.
| Situation | What the discussion is really about |
|---|---|
| A single dose a few days late | Confirming the labeled window applies and resetting the anchor day |
| One full week missed | Whether to resume as scheduled and what to watch afterward |
| Several weeks missed | Whether tolerance has faded enough to warrant restarting lower |
| Repeated missed weeks | Why, since cost, side effects, and supply need different fixes |
| Stopping without a plan | What replaces it and how glycemic control will be maintained |
| Moving the injection day | Keeping the labeled minimum interval between two doses |
Most gaps are supply problems, not forgetfulness
Real-world follow-up shows a substantial share of patients no longer on semaglutide at twelve months, and the reasons cluster around cost, insurance friction, and interruptions in access rather than around a decision that the drug had failed. Prior authorization lapses, formulary changes, and pharmacy backorders all produce the same missed weeks that look like non-adherence in a chart.
This is worth naming honestly at the appointment. A prescriber who thinks the patient forgot will suggest reminders. A prescriber who knows the pharmacy could not fill the order will address coverage, which is a different problem with different solutions, and Medicare’s own coverage rules for prescription drugs are one of the places those solutions are found.
Continuity is the thing to check before signing up
How a provider handles an interruption is the clearest test of whether the service is a care relationship or a fulfillment channel. The question worth asking is what happens when a shipment is late, when a refill is denied, or when a patient goes three weeks without product.
Answers differ across the field. A primary care or endocrinology practice can substitute or bridge with something else in the chart. Manufacturer-run channels such as NovoCare Pharmacy and LillyDirect control their own supply for the branded product. Direct-to-consumer telehealth companies including Ro, Hims & Hers, LifeMD, and FormBlends each have their own process for gaps and their own cost structure behind it. Asking about that process before starting is more useful than discovering it during a missed month.
Compounded preparations have no equivalent rule
The five-day statement comes from the approved product’s labeling. Compounded semaglutide is not FDA-approved, has no labeling reviewed by the agency, and varies in concentration between pharmacies, so nothing in the branded label transfers to it.
That means a patient using a compounded preparation who misses a week has no published rule to fall back on. The prescriber who wrote it is the source of the answer, and clinicians writing about compounded semaglutide have made the point that the absence of a standardized product is precisely what removes the shortcuts.
Frequently asked questions
Does a missed week undo previous progress?
Usually not in any lasting way. A single missed week is a short interruption to a long half-life drug. Repeated gaps are the pattern that matters, because control drifts and tolerance fades across weeks rather than days.
Can a double amount be given to catch up?
No. Nothing in the labeling supports giving extra to compensate, and doing so raises the risk of gastrointestinal effects without a corresponding benefit. Where a gap has been long, the correct step is a conversation about resuming, not arithmetic.
Is the injection day fixed permanently?
No. The labeling allows the weekly day to be changed when needed, as long as a minimum interval separates two doses. Frequent shifting still makes it harder to spot a pattern, so a stable day remains preferable where the schedule allows.
What if the pharmacy cannot fill the prescription?
Report it as a clinical issue rather than waiting. A supply gap has the same effect as stopping, and prescribers have options such as alternate agents or coverage appeals that only become available once they know the interruption is happening.
Does stopping entirely require any plan?
For type 2 diabetes, yes. Glycemic control drifts back after treatment ends, so ending therapy means deciding what maintains control instead. An unplanned stop and a planned one produce different outcomes for the same reason.
